New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait!

Chest

Volumn 152, Issue 6, 2017, Pages 1276-1282

  Bel, Elisabeth H ^a   ten Brinke, Anneke ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MEDICAL CENTER LEEUWARDEN   (Netherlands)

Author keywords

airway inflammation; asthma; COPD; eosinophils; pharmacotherapy

Indexed keywords

BENRALIZUMAB; CORTICOSTEROID; DUPILUMAB; FEVIPIPRANT; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 25; INTERLEUKIN 33; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 5; INTERLEUKIN 5 RECEPTOR; LEBRIKIZUMAB; MEPOLIZUMAB; OMALIZUMAB; PLACEBO; RESLIZUMAB; TEZEPELUMAB; THYMIC STROMAL LYMPHOPOIETIN; TIMAPIPRANT; TRALOKINUMAB; ANTIASTHMATIC AGENT; BIOLOGICAL FACTOR;

ADAPTIVE IMMUNITY; ADD ON THERAPY; ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; EOSINOPHIL; HUMAN; INNATE IMMUNITY; LYMPHOID CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW; TH2 CELL; DRUG EFFECTS; INFLAMMATION; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

ANTI-ASTHMATIC AGENTS; ASTHMA; BIOLOGICAL FACTORS; EOSINOPHILS; HUMANS; INFLAMMATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 85036659397     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2017.05.019     Document Type: Review

References (50)

1. To, T., Stanojevic, S., Moores, G., et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health, 12, 2012, 204.
2. Barnes, P.J., Asthma-COPD overlap. Chest 149:1 (2016), 7–8.
3. Agusti, A., Bel, E., Thomas, M., et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 47:2 (2016), 410–419.
4. Bush, A., Kleinert, S., Pavord, I.D., The asthmas in 2015 and beyond: a Lancet Commission. Lancet 385:9975 (2015), 1273–1275.
5. Dweik, R.A., Sorkness, R.L., Wenzel, S., et al. National Heart, Lung, and Blood Institute Severe Asthma Research Program. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. Am J Respir Crit Care Med 181:10 (2010), 1033–1041.
6. Green, R.H., Brightling, C.E., McKenna, S., et al. Asthma exacerbations and sputum eosinophil counts: a randomized controlled trial. Lancet 360:9347 (2002), 1715–1721.
7. de Groot, J.C., Storm, H., Amelink, M., et al. Clinical profile of patients with adult-onset eosinophilic asthma. ERJ Open Res, 2(2), 2016.
8. Sweeney, J., Patterson, C.C., Menzies-Gow, A., et al. British Thoracic Society Difficult Asthma Network. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient CareResearch Database and the British Thoracic Difficult Asthma Registry. Thorax 71:4 (2016), 339–346.
9. Nixon, J., Newbold, P., Mustelin, T., Anderson, G.P., Kolbeck, R., Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation. Pharmacol Ther 169 (2017), 57–77.
10. Rosenberg, H.F., Dyer, K.D., Foster, P.S., Eosinophils: changing perspectives in health and disease. Nat Rev Immunol 13:1 (2013), 9–22.
11. Bochner, B.S., Gleich, G.J., What targeting eosinophils has taught us about their role in diseases. J Allergy Clin Immunol 126:1 (2010), 16–25.
12. de Magalhães Simões, S., dos Santos, M.A., da Silva Oliveira, M., et al. Inflammatory cell mapping of the respiratory tract in fatal asthma. Clin Exp Allergy 35:5 (2005), 602–611.
13. Chung, K.F., Targeting the interleukin pathway in the treatment of asthma. Lancet 386:9998 (2015), 1086–1096.
14. Leigh, R., Pizzichini, M.M., Morris, M.M., Maltais, F., Hargreave, F.E., Pizzichini, E., Stable, C.O.P.D., predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 27:5 (2006), 964–971.
15. Couillard, S., Larivée, P., Courteau, J., Vanasse, A., Eosinophils in COPD exacerbations are associated with increased readmissions. Chest 151:2 (2017), 366–373.
16. Brightling, C.E., Monteiro, W., Ward, R., et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 356:9240 (2000), 1480–1485.
17. Bafadhel, M., Greening, N.J., Harvey-Dunstan, T.C., et al. Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD. Chest 150:2 (2016), 320–328.
18. Siva, R., Green, R.H., Brightling, C.E., et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 29:5 (2007), 906–913.
19. Brusselle, G.G., Maes, T., Bracke, K.R., Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nat Med 19:8 (2013), 977–979.
20. Lambrecht, B.N., Hammad, H., The immunology of asthma. Nat Immunol 16:1 (2015), 45–56.
21. Keating, G.M., Mepolizumab: first global approval. Drugs 75:18 (2015), 2163–2169.
22. Markham, A., Reslizumab: first global approval. Drugs 76:8 (2016), 907–911.
23. Anonymous. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody—GlaxoSmithKline, SB 240563. Drugs R D 9:2 (2008), 125–130.
24. Leckie, M.J., ten Brinke, A., Khan, J., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356:9248 (2000), 2144–2148.
25. Haldar, P., Brightling, C.E., Hargadon, B., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360:10 (2009), 973–984.
26. Nair, P., Pizzichini, M.M., Kjarsgaard, M., et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 360:10 (2009), 985–993.
27. Pavord, I.D., Korn, S., Howarth, P., et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380:9842 (2012), 651–659.
28. Ortega, H.G., Liu, M.C., Pavord, I.D., et al., MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371:13 (2014), 1198–1207.
29. Bel, E.H., Wenzel, S.E., Thompson, P.J., et al., SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371:13 (2014), 1189–1197.
30. Haldar, P., Brightling, C.E., Singapuri, A., et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol 133:3 (2014), 921–923.
31. Kips, J.C., O'Connor, B.J., Langley, S.J., et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 167:12 (2003), 1655–1659.
32. Castro, M., Mathur, S., Hargreave, F., et al., Res-5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 184:10 (2011), 1125–1132.
33. Castro, M., Zangrilli, J., Wechsler, M.E., et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, Phase 3 trials. Lancet Respir Med 3:5 (2015), 355–366.
34. Ghazi, A., Trikha, A., Calhoun, W.J., Benralizumab—a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity—a novel approach for the treatment of asthma. Expert Opin Biol Ther 12:1 (2012), 113–118.
35. Castro, M., Wenzel, S.E., Bleecker, E.R., et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a Phase 2b randomised dose-ranging study. Lancet Respir Med 2:11 (2014), 879–890.
36. Bleecker, E.R., FitzGerald, J.M., Chanez, P., et al., SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled Phase 3 trial. Lancet 388:10056 (2016), 2115–2127.
37. FitzGerald, J.M., Bleecker, E.R., Nair, P., et al., CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled Phase 3 trial. Lancet 388:10056 (2016), 2128–2141.
38. Brightling, C.E., Bleecker, E.R., Panettieri, R.A. Jr., et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, Phase 2a study. Lancet Respir Med 2:11 (2014), 891–901.
39. Djukanović R., Wilson, S.J., Kraft, M., et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 170:6 (2004), 583–593.
40. Massanari, M., Holgate, S.T., Busse, W.W., Jimenez, P., Kianifard, F., Zeldin, R., Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir Med 104:2 (2010), 188–196.
41. Normansell, R., Walker, S., Milan, S.J., Walters, E.H., Nair, P., Omalizumab for asthma in adults and children. Cochrane Database Syst Rev(1), 2014, CD003559.
42. Maltby, S., Gibson, P.G., Powell, H., McDonald, V.M., Omalizumab treatment response in a population with severe allergic asthma and overlapping COPD. Chest 151:1 (2017), 78–89.
43. Hanania, N.A., Noonan, M., Corren, J., et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 70:8 (2015), 748–756.
44. Piper, E., Brightling, C., Niven, R., et al. A Phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 41:2 (2013), 330–338.
45. Brightling, C.E., Chanez, P., Leigh, R., et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, Phase 2b trial. Lancet Respir Med 3:9 (2015), 692–701.
46. Wenzel, S., Castro, M., Corren, J., et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal Phase 2b dose-ranging trial. Lancet 388:10039 (2016), 31–44.
47. Gonem, S., Berair, R., Singapuri, A., et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med 4:9 (2016), 699–707.
48. Snell, N., Foster, M., Vestbo, J., Efficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD. Respir Med 107:11 (2013), 1722–1730.
49. Gauvreau, G.M., O'Byrne, P.M., Boulet, L.P., et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 370:22 (2014), 2102–2110.
50. Hanania, N.A., Wenzel, S., Rosén, K., et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 187:8 (2013), 804–811.